Codagenix is a clinical-stage synthetic biology company focused on designing live-attenuated vaccines and viral therapeutics using codon deoptimization. The platform combines live-attenuated virus design with synthetic biology techniques to address infectious disease, cancer, and animal health. Led by CEO J. Robert Coleman and based in Farmingdale, New York, the company develops intranasal and universal vaccine candidates. Its lead clinical programs include CodaVax-RSV, an intranasal live-attenuated RSV vaccine candidate, and CodaVax-H1N1, a universal live-attenuated influenza vaccine currently in an ongoing Phase 1 study. The company also plans to expand its oncology program. The recent financing is intended to advance clinical development and support additional cohorts in ongoing studies. Codagenix is a clinical-stage biotechnology company based in Farmingdale, N.Y., that uses software to recode viral genomes to construct live-attenuated vaccines and oncolytic viruses. Its platform produces recoded vaccine candidates that match target viruses and induce immune responses to all viral antigens, and can be used to turn viruses into potential oncolytic immuno-oncology therapies. Led by CEO J. Robert Coleman, the company plans to use the Series B proceeds to advance clinical development of a live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine, and an oncolytic therapy for triple negative breast cancer. Codagenix spun out of the laboratory of National Academy of Science member Eckard Wimmer at Stony Brook University in 2012. The company closed a $20m Series B and, together with Series A investments, has raised $38m to date; previous funders include Topspin Partners, The Stony Brook University Center for Biotechnology and U.S. government agencies. Codagenix is a Long Island, New York–based pre-clinical biotechnology company that develops live-attenuated vaccines using a software-based rational design algorithm which re-structures viral genomes into a sub-optimal genetic code. The company’s platform is built to produce ultra-low dose live-attenuated vaccines. Its pipeline includes influenza, respiratory syncytial virus (RSV), dengue, foot-and-mouth disease virus (FMDV), pathogenic E. coli and other targets. Codagenix was co-founded by Steffen Mueller (President and Chief Scientific Officer), J. Robert Coleman (Chief Operating Officer), and Stony Brook. The company intends to use newly raised funds to expand its vaccine targets and to support clinical testing of its ultra-low dose live-attenuated influenza vaccine. Financially, Codagenix completed a $2M Series A financing to advance these efforts.

Total raised

$47M

Funding rounds

3

Latest round

Series B

Latest activity

Feb 2023